The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: a single-center experience

References

• Kaufmann M, Von Minckwitz G, Bear H, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–1934. doi:10.1093/annonc/mdm201.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–1516. doi:10.1245/s10434-011-2108-2.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–2608. doi:10.1200/JCO.2003.01.136.
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–785. doi:10.1200/JCO.2007.15.0235.
   PubMed Web of Science ®Google Scholar
• Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:1821–1828. doi:10.1200/JCO.2009.25.3286.
   PubMed Web of Science ®Google Scholar
• Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18:932–938. doi:10.1245/s10434-010-1390-8.
   PubMed Web of Science ®Google Scholar
• Raphael J, Paramsothy T, Li N, Lee J, Gandhi S. A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017;163:11–19. doi:10.1007/s10549-017-4167-y.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015:136(5):E359–386. doi:10.1002/ijc.29210.
   Web of Science ®Google Scholar
• Leong SP, Shen -Z-Z, Liu T-J, Agarwal G, Tajima T, Paik N-S, Sandelin K, Derossis A, Cody H, Foulkes WD. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308–2324. doi:10.1007/s00268-010-0683-1.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu M-C, Martin M, Namer M. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401. doi:10.3816/CBC.2005.n.043.
   PubMedGoogle Scholar
• Bhoo-Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Ho GF, Looi LM, Bulgiba AM, van der Graaf Y, Verkooijen HM. Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012;48:982–989. doi:10.1016/j.ejca.2012.01.034.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, Abraham S, Nayeemuddin K, Hunt K, Wu Y. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer. 2010;116:4463–4473. doi:10.1002/cncr.25352.
   PubMed Web of Science ®Google Scholar
• Chen L, Fan Y, Lang R, Guo X, Sun Y, Fu L. Diagnosis and prognosis study of breast carcinoma with micropapillary component. Zhonghua Bing Li Xue Za Zhi= Chin J Pathol. 2007;36:228–232.
   PubMedGoogle Scholar
• Wu X, Zhang Z, Li X, Lin Q, Chen G, Lu J, Zeng Y, Hu D, Huang K, Lin Z. Poorer prognosis of primary signet-ring cell carcinoma of the breast compared with Mucinous carcinoma. PLoS One. 2016;11:e0162088. doi:10.1371/journal.pone.0162088.
   PubMed Web of Science ®Google Scholar
• Merino MJ, Livolsi VA. Signet ring carcinoma of the female breast: a clinicopathologic analysis of 24 cases. Cancer. 1981;48:1830–1837. doi:10.1002/1097-0142(19811015)48:8<1830::AID-CNCR2820480821>3.0.CO;2-H.
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Liu -B-B, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: an update. Arch Pathol Lab Med. 2016;140:799–805. doi:10.5858/arpa.2016-0040-RA.
   PubMed Web of Science ®Google Scholar
• Kanat O, Kilickap S, Korkmaz T, Oven BBU, Canhoroz M, Cubukcu E, Tolunay S, Evrensel T, Manavoglu O. Primary small cell carcinoma of the breast: report of seven cases and review of the literature. Tumori J. 2011;97:473–478. doi:10.1177/030089161109700410.
   PubMed Web of Science ®Google Scholar
• Lim SZ, Ong KW, Tan BKT, Selvarajan S, Tan PH. Sarcoma of the breast: an update on a rare entity. J Clin Pathol. 2016;69(5):373–381. doi:10.1136/jclinpath-2015-203545.
   Google Scholar
• Tanabe Y, Tsuda H, Yoshida M, Yunokawa M, Yonemori K, Shimizu C, Yamamoto S, Kinoshita T, Fujiwara Y, Tamura K. Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancer Sci. 2017;108:1520–1529. doi:10.1111/cas.13274.
   PubMed Web of Science ®Google Scholar
• Hennessy B, Giordano S, Broglio K, Duan Z, Trent J, Buchholz T, Babiera G, Hortobagyi G, Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605–613. doi:10.1093/annonc/mdl006.
   PubMed Web of Science ®Google Scholar
• Chen I, Lin C, Huang C, Lien H, Hsu C, Kuo W, Lu Y, Cheng A. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130:345. doi:10.1007/s10549-011-1686-9.
   PubMed Web of Science ®Google Scholar
• Bear HD, Anderson S, Smith RE, Jr CE G, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2006;24:2019–2027. doi:10.1200/JCO.2005.04.1665.
   PubMed Web of Science ®Google Scholar
• Goble S, Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am. 2003;83:943–971. doi:10.1016/S0039-6109(03)00071-9.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31:3623–3630. doi:10.1200/JCO.2012.45.0940.
   PubMed Web of Science ®Google Scholar
• Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–1466. doi:10.1200/JCO.2002.20.6.1456.
   PubMed Web of Science ®Google Scholar
• Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3:S69–S74. doi:10.3816/CBC.2002.s.015.
   PubMedGoogle Scholar
• Alba E, Calvo L, Albanell J, De la Haba J, Arcusa Lanza A, Chacon J, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo J, Chemotherapy BB. (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23:3069–3074. doi:10.1093/annonc/mds132.
   PubMed Web of Science ®Google Scholar
• Berruti A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, Bottini A. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist. 2008;13:1137–1148. doi:10.1634/theoncologist.2008-0162.
   PubMed Web of Science ®Google Scholar
• Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V. du Bois A, Kühn T. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351–3357.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13–20. doi:10.1002/ijc.2910310104.
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24:2786–2793. doi:10.1093/annonc/mdt350.
   PubMed Web of Science ®Google Scholar
• Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30:3242. doi:10.1200/JCO.2011.39.2779.
   PubMed Web of Science ®Google Scholar
• Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, JAL G-A, Palacios J, Chacon JI. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer. Oncologist. 2016;21:150–155. doi:10.1634/theoncologist.2015-0312.
   PubMed Web of Science ®Google Scholar
• Lee JK, Coutant C, Kim Y-C, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010;1078–0432:CCR-09-2247.
   Google Scholar
• Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, De Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633–640. doi:10.1016/S0140-6736(11)61847-3.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch A, Staroslawska E, de la Haba-rodriguez J, Im S-A. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32. doi:10.1016/S1470-2045(11)70336-9.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, et al. A Nation-Wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer. 2011;11:364. doi:10.1186/1471-2407-11-364.
   PubMedGoogle Scholar
• Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. JNCI Monogr. 2001;2001:96–102. doi:10.1093/oxfordjournals.jncimonographs.a003469.
   Google Scholar
• Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650–2655. doi:10.1200/JCO.2006.08.2271.
   PubMed Web of Science ®Google Scholar